Skip to content
Catalyst
Scale for the Assessment of Negative Symptoms (SANS) total score

1 finding · 1 compound · 1 null · by evidence strength. No dose is advised.

Fig. 2 Scale for the Assessment of Negative Symptoms (SANS) total score1 compound outer ring on requestSelected Scale for the Assessment of Negative Symptoms (SANS) total score · centre
×1.60
Labels
Measured outcomeInspector

Scale for the Assessment of Negative Symptoms (SANS) total score

Findings drawn, by strength

1finding · 1 compound

  • Very limited1
Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

Compound no difference foundFindingsStrongest
1
Very limited

Not pooled · no summary effect · point at a mark · Tab, then the arrow keys

Measured, no difference found1 finding

  1. GlycineMoved: no difference foundEvidence: Very limitedPaper: PMID 178983522007
    Who
    Inpatients and outpatients with schizophrenia or schizoaffective disorder and moderate to severe negative symptoms, adjunctive glycine against placebo; the D-cycloserine arm is a separate comparison against the same placebo
    Dose studied
    not reported

    There were no significant differences in change in the SANS total score between glycine and placebo subjects or D-cycloserine and placebo subjects.”

    Quoted verbatim from The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.RCT · 4 monthsPermalink

How it is measured

Total score on the Scale for the Assessment of Negative Symptoms (SANS; Andreasen 1982 and 1984), a clinician-rated scale of 25 items in five domains (affective flattening or blunting, alogia, avolition-apathy, anhedonia-asociality and attention), each rated 0 (none) to 5 (severe); the total is the sum of all items (0 to 125), or the sum of the five global domain ratings (0 to 25), which the source states; higher is worse.

Measured, with no finding

1 measurement

Show what was measuredHide what was measured
  • Scale for the Assessment of Negative Symptoms (SANS) total score

    no effect

    Not recorded as a finding: Agentless passive covering four outcomes in one sentence and never naming the compound.

    No significant within- or between-group changes were observed for PANSS positive, SANS, CDRS, or MATRICS composite scores (Table 2).

    PMID 28289280 · one of two readings recorded this

Papers about it

As an endpoint4

Show the papersHide the papers
  • Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.

    Molecular psychiatry2018PMID 28289280Via: named in the paper, as read

  • Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.

    Psychiatry and clinical neurosciences2014PMID 24548129Via: named in the paper, as read

  • Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.

    Neuropsychopharmacology2009PMID 19339966Via: named in the paper, as read

  • The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

    The American journal of psychiatry2007PMID 17898352Via: named in the paper, as read

Newest

  • Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.

    Molecular psychiatry2018PMID 28289280As an endpoint

  • Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.

    Psychiatry and clinical neurosciences2014PMID 24548129As an endpoint

  • Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.

    Neuropsychopharmacology2009PMID 19339966As an endpoint

  • The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

    The American journal of psychiatry2007PMID 17898352As an endpoint